Biotech startup Exsure raised Rs 3 Cr Seed funding from Unicorn India Ventures
In a seed round headed by Unicorn India Ventures, the biotech startup Exsure has raised Rs 3 crore.
According to a press release from the company, the new funding will be utilized to finish the non-clinical study of its exosome-based drug delivery platform, support its plans for international expansion with in-house R&D products, and advertise its products, which include Exosure, Leucosure, PlantExosure, and Dr. Berries.
Exsure, a biotech startup co-founded in 2021 by Swastika Paul and Abhishek Dutta, aims to lessen the toxicity and adverse effects of anti-cancer medications by using its patented exosomal drug-delivery platform, which targets cancer and cancer stem cells.
The company hopes to improve cancer patients’ quality of life by minimizing the harmful effects of chemotherapy and lowering the chance of cancer recurrence with its state-of-the-art technology.
In the last 12 months, Exsure has finished preclinical research using its patented technology and started a non-clinical study in India in partnership with a CRO. The business has acquired partners and collaborators throughout India for its goods and services, and it has introduced its first in-house produced goods.
Market research projects that the Indian biotechnology sector will be worth $150 billion by 2025 and could reach $270–300 billion by 2030.
With its R&D products, which include Exosure (a 3-in-1 exosome isolation reagent), Leucosure (a PBMC isolation reagent), and PlantExosure (India’s first plant exosome isolation reagent), the Bhubaneswar-based company reported a fivefold increase in the previous fiscal year and is on track to serve over 50 clients this year. The business has also been chosen to participate in clinical trials and business expansion through the OIST Innovation Accelerator Program in Japan.
